_id
69148719ccc777a4e85d96c8
Ticker
OGN
Name
Organon & Co
Exchange
NYSE
Address
30 Hudson Street, Jersey City, NJ, United States, 07302
Country
USA
Sector
Healthcare
Industry
Drug Manufacturers - General
Currency
USD
Website
https://www.organon.com
Description
Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding or hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
Last Close
7.36
Volume
3903793
Current Price
7.17
Change
-2.58152173913044
Last Updated
2025-12-02T13:00:34.949Z
Image
data:image/webp;base64,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
Ipo Date
2021-06-02T00:00:00.000Z
Market Cap
1975870080
Next Dividend Date
2025-12-11T00:00:00.000Z
Dividend Frequency
Quarterly
Dividend Rate
0.02
Dividend Yield
1.1157601115760112
Sentiment
0.8663095238095238
Sentiment Sources
42
Rating
3
Target Price
9.6667
Strong Buy
0
Buy
2
Hold
3
Sell
2
Strong Sell
0
Current Quarter
2025-09-30
Revenue
1602000000
Cost Of Revenue
745000000
Gross Profit
857000000
Operating Expenses
499000000
Operating Income
358000000
Interest Expense
128000000
Pretax Income
243000000
Net Income
160000000
Eps
0.6138429252684604
Dividends Per Share
3000000
Shares Outstanding
259982912
Income Tax Expense
83000000
EBITDA
460000000
Operating Margin
22.347066167290887
Total Other Income Expense Net
-115000000
Cash
672000000
Short Term Investments
-
Receivables
1484000000
Inventories
1488000000
Total Current Assets
4700000000
Property Plant Equipment
1290000000
Total Assets
13552000000
Payables
1074000000
Short Term Debt
45000000
Long Term Debt
8783000000
Total Liabilities
12646000000
Equity
906000000
Depreciation
92000000
Change In Working Capital
-27000000
Cash From Operations
264000000
Capital Expenditures
115000000
Cash From Investing
-115000000
Cash From Financing
-76000000
Net Change In Cash
73000000
PE
3.9791
PB
2.062783675496689
ROE
17.660044150110377
ROA
1.1806375442739079
FCF
149000000
Fcf Percent
0.09300873907615481
Piotroski FScore
4
Health Score
55
Deep Value Investing Score
7
Defensive Investing Score
7.5
Dividend Investing Score
4
Economic Moat Investing Score
7.3
Garp Investing Score
6
Growth Investing Score
4.5
Momentum Investing Score
4
Net Net Investing Score
3
Quality Investing Score
5.5
Value Investing Score
7.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
1602000000
Quarters > 0 > income Statement > cost Of Revenue
745000000
Quarters > 0 > income Statement > gross Profit
857000000
Quarters > 0 > income Statement > operating Expenses
499000000
Quarters > 0 > income Statement > operating Income
358000000
Quarters > 0 > income Statement > interest Expense
128000000
Quarters > 0 > income Statement > pretax Income
243000000
Quarters > 0 > income Statement > net Income
160000000
Quarters > 0 > income Statement > eps
0.6138429252684604
Quarters > 0 > income Statement > dividends Per Share
3000000
Quarters > 0 > income Statement > shares Outstanding
260653000
Quarters > 0 > income Statement > income Tax Expense
83000000
Quarters > 0 > income Statement > EBITDA
460000000
Quarters > 0 > income Statement > operating Margin
22.347066167290887
Quarters > 0 > income Statement > total Other Income Expense Net
-115000000
Quarters > 0 > balance Sheet > cash
672000000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
1484000000
Quarters > 0 > balance Sheet > inventories
1488000000
Quarters > 0 > balance Sheet > total Current Assets
4700000000
Quarters > 0 > balance Sheet > property Plant Equipment
1290000000
Quarters > 0 > balance Sheet > total Assets
13552000000
Quarters > 0 > balance Sheet > payables
1074000000
Quarters > 0 > balance Sheet > short Term Debt
45000000
Quarters > 0 > balance Sheet > long Term Debt
8783000000
Quarters > 0 > balance Sheet > total Liabilities
12646000000
Quarters > 0 > balance Sheet > equity
906000000
Quarters > 0 > cash Flow > net Income
160000000
Quarters > 0 > cash Flow > depreciation
92000000
Quarters > 0 > cash Flow > change In Working Capital
-27000000
Quarters > 0 > cash Flow > cash From Operations
264000000
Quarters > 0 > cash Flow > capital Expenditures
115000000
Quarters > 0 > cash Flow > cash From Investing
-115000000
Quarters > 0 > cash Flow > cash From Financing
-76000000
Quarters > 0 > cash Flow > net Change In Cash
73000000
Quarters > 0 > ratios > PE
0.6138429252684604
Quarters > 0 > ratios > PB
2.062783675496689
Quarters > 0 > ratios > ROE
17.660044150110377
Quarters > 0 > ratios > ROA
1.1806375442739079
Quarters > 0 > ratios > FCF
149000000
Quarters > 0 > ratios > Piotroski FScore
4
Quarters > 0 > ratios > fcf Percent
0.09300873907615481
Quarters > 0 > health Score
55
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
1594000000
Quarters > 1 > income Statement > cost Of Revenue
720000000
Quarters > 1 > income Statement > gross Profit
874000000
Quarters > 1 > income Statement > operating Expenses
548000000
Quarters > 1 > income Statement > operating Income
326000000
Quarters > 1 > income Statement > interest Expense
132000000
Quarters > 1 > income Statement > pretax Income
229000000
Quarters > 1 > income Statement > net Income
145000000
Quarters > 1 > income Statement > eps
0.5573578929565338
Quarters > 1 > income Statement > dividends Per Share
10000000
Quarters > 1 > income Statement > shares Outstanding
260156000
Quarters > 1 > income Statement > income Tax Expense
84000000
Quarters > 1 > income Statement > EBITDA
449000000
Quarters > 1 > income Statement > operating Margin
20.451693851944793
Quarters > 1 > income Statement > total Other Income Expense Net
-97000000
Quarters > 1 > balance Sheet > cash
599000000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
1511000000
Quarters > 1 > balance Sheet > inventories
1454000000
Quarters > 1 > balance Sheet > total Current Assets
4618000000
Quarters > 1 > balance Sheet > property Plant Equipment
1266000000
Quarters > 1 > balance Sheet > total Assets
13500000000
Quarters > 1 > balance Sheet > payables
1067000000
Quarters > 1 > balance Sheet > short Term Debt
115000000
Quarters > 1 > balance Sheet > long Term Debt
8781000000
Quarters > 1 > balance Sheet > total Liabilities
12767000000
Quarters > 1 > balance Sheet > equity
733000000
Quarters > 1 > cash Flow > net Income
145000000
Quarters > 1 > cash Flow > depreciation
89000000
Quarters > 1 > cash Flow > change In Working Capital
-109000000
Quarters > 1 > cash Flow > cash From Operations
220000000
Quarters > 1 > cash Flow > capital Expenditures
39000000
Quarters > 1 > cash Flow > cash From Investing
-38000000
Quarters > 1 > cash Flow > cash From Financing
-223000000
Quarters > 1 > cash Flow > net Change In Cash
52000000
Quarters > 1 > ratios > PE
0.5573578929565338
Quarters > 1 > ratios > PB
2.5447728785811736
Quarters > 1 > ratios > ROE
19.781718963165076
Quarters > 1 > ratios > ROA
1.074074074074074
Quarters > 1 > ratios > FCF
181000000
Quarters > 1 > ratios > Piotroski FScore
4
Quarters > 1 > ratios > fcf Percent
0.11355081555834379
Quarters > 1 > health Score
59
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
1513000000
Quarters > 2 > income Statement > cost Of Revenue
672000000
Quarters > 2 > income Statement > gross Profit
841000000
Quarters > 2 > income Statement > operating Expenses
516000000
Quarters > 2 > income Statement > operating Income
325000000
Quarters > 2 > income Statement > interest Expense
124000000
Quarters > 2 > income Statement > pretax Income
101000000
Quarters > 2 > income Statement > net Income
87000000
Quarters > 2 > income Statement > eps
0.3333320561990184
Quarters > 2 > income Statement > dividends Per Share
71000000
Quarters > 2 > income Statement > shares Outstanding
261001000
Quarters > 2 > income Statement > income Tax Expense
14000000
Quarters > 2 > income Statement > EBITDA
325000000
Quarters > 2 > income Statement > operating Margin
21.480502313284862
Quarters > 2 > income Statement > total Other Income Expense Net
-224000000
Quarters > 2 > balance Sheet > cash
547000000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
1467000000
Quarters > 2 > balance Sheet > inventories
1362000000
Quarters > 2 > balance Sheet > total Current Assets
4371000000
Quarters > 2 > balance Sheet > property Plant Equipment
1197000000
Quarters > 2 > balance Sheet > total Assets
13156000000
Quarters > 2 > balance Sheet > payables
1006000000
Quarters > 2 > balance Sheet > short Term Debt
20000000
Quarters > 2 > balance Sheet > long Term Debt
8936000000
Quarters > 2 > balance Sheet > total Liabilities
12614000000
Quarters > 2 > balance Sheet > equity
542000000
Quarters > 2 > cash Flow > net Income
87000000
Quarters > 2 > cash Flow > depreciation
84000000
Quarters > 2 > cash Flow > change In Working Capital
-125000000
Quarters > 2 > cash Flow > cash From Operations
75000000
Quarters > 2 > cash Flow > capital Expenditures
97000000
Quarters > 2 > cash Flow > cash From Investing
-172000000
Quarters > 2 > cash Flow > cash From Financing
-75000000
Quarters > 2 > cash Flow > net Change In Cash
-128000000
Quarters > 2 > ratios > PE
0.3333320561990184
Quarters > 2 > ratios > PB
3.452725405904059
Quarters > 2 > ratios > ROE
16.051660516605164
Quarters > 2 > ratios > ROA
0.6612952265126179
Quarters > 2 > ratios > FCF
-22000000
Quarters > 2 > ratios > Piotroski FScore
3
Quarters > 2 > ratios > fcf Percent
-0.014540647719762063
Quarters > 2 > health Score
40
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
1592000000
Quarters > 3 > income Statement > cost Of Revenue
696000000
Quarters > 3 > income Statement > gross Profit
896000000
Quarters > 3 > income Statement > operating Expenses
600000000
Quarters > 3 > income Statement > operating Income
296000000
Quarters > 3 > income Statement > interest Expense
132000000
Quarters > 3 > income Statement > pretax Income
129000000
Quarters > 3 > income Statement > net Income
109000000
Quarters > 3 > income Statement > eps
0.41942757755562227
Quarters > 3 > income Statement > dividends Per Share
74000000
Quarters > 3 > income Statement > shares Outstanding
259878000
Quarters > 3 > income Statement > income Tax Expense
20000000
Quarters > 3 > income Statement > EBITDA
341000000
Quarters > 3 > income Statement > operating Margin
18.592964824120603
Quarters > 3 > income Statement > total Other Income Expense Net
-167000000
Quarters > 3 > balance Sheet > cash
675000000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
1491000000
Quarters > 3 > balance Sheet > inventories
1321000000
Quarters > 3 > balance Sheet > total Current Assets
4348000000
Quarters > 3 > balance Sheet > property Plant Equipment
1325000000
Quarters > 3 > balance Sheet > total Assets
13101000000
Quarters > 3 > balance Sheet > payables
1153000000
Quarters > 3 > balance Sheet > short Term Debt
64000000
Quarters > 3 > balance Sheet > long Term Debt
8860000000
Quarters > 3 > balance Sheet > total Liabilities
12629000000
Quarters > 3 > balance Sheet > equity
472000000
Quarters > 3 > cash Flow > net Income
109000000
Quarters > 3 > cash Flow > depreciation
77000000
Quarters > 3 > cash Flow > change In Working Capital
112000000
Quarters > 3 > cash Flow > cash From Operations
390000000
Quarters > 3 > cash Flow > capital Expenditures
132000000
Quarters > 3 > cash Flow > cash From Investing
-296000000
Quarters > 3 > cash Flow > cash From Financing
-82000000
Quarters > 3 > cash Flow > net Change In Cash
-88000000
Quarters > 3 > ratios > PE
0.41942757755562227
Quarters > 3 > ratios > PB
3.947723008474576
Quarters > 3 > ratios > ROE
23.093220338983052
Quarters > 3 > ratios > ROA
0.8319975574383635
Quarters > 3 > ratios > FCF
258000000
Quarters > 3 > ratios > Piotroski FScore
4
Quarters > 3 > ratios > fcf Percent
0.1620603015075377
Quarters > 3 > health Score
58
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
6403000000
Annuals > 0 > income Statement > cost Of Revenue
2688000000
Annuals > 0 > income Statement > gross Profit
3715000000
Annuals > 0 > income Statement > operating Expenses
2229000000
Annuals > 0 > income Statement > operating Income
1486000000
Annuals > 0 > income Statement > interest Expense
520000000
Annuals > 0 > income Statement > pretax Income
807000000
Annuals > 0 > income Statement > net Income
864000000
Annuals > 0 > income Statement > eps
3.3339507316169663
Annuals > 0 > income Statement > dividends Per Share
297000000
Annuals > 0 > income Statement > shares Outstanding
259152000
Annuals > 0 > income Statement > income Tax Expense
-57000000
Annuals > 0 > income Statement > EBITDA
1604000000
Annuals > 0 > income Statement > operating Margin
23.207871310323284
Annuals > 0 > income Statement > total Other Income Expense Net
-679000000
Annuals > 0 > balance Sheet > cash
675000000
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
1491000000
Annuals > 0 > balance Sheet > inventories
1321000000
Annuals > 0 > balance Sheet > total Current Assets
4348000000
Annuals > 0 > balance Sheet > property Plant Equipment
1325000000
Annuals > 0 > balance Sheet > total Assets
13101000000
Annuals > 0 > balance Sheet > payables
1153000000
Annuals > 0 > balance Sheet > short Term Debt
64000000
Annuals > 0 > balance Sheet > long Term Debt
8860000000
Annuals > 0 > balance Sheet > total Liabilities
12629000000
Annuals > 0 > balance Sheet > equity
472000000
Annuals > 0 > cash Flow > net Income
864000000
Annuals > 0 > cash Flow > depreciation
277000000
Annuals > 0 > cash Flow > change In Working Capital
-278000000
Annuals > 0 > cash Flow > cash From Operations
939000000
Annuals > 0 > cash Flow > capital Expenditures
351000000
Annuals > 0 > cash Flow > cash From Investing
-513000000
Annuals > 0 > cash Flow > cash From Financing
-368000000
Annuals > 0 > cash Flow > net Change In Cash
-18000000
Annuals > 0 > ratios > PE
3.3339507316169663
Annuals > 0 > ratios > PB
4.172786440677966
Annuals > 0 > ratios > ROE
183.05084745762713
Annuals > 0 > ratios > ROA
6.594916418594001
Annuals > 0 > ratios > FCF
588000000
Annuals > 0 > ratios > Piotroski FScore
4
Annuals > 0 > ratios > fcf Percent
0.09183195377166953
Annuals > 0 > health Score
57
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
6263000000
Annuals > 1 > income Statement > cost Of Revenue
2515000000
Annuals > 1 > income Statement > gross Profit
3748000000
Annuals > 1 > income Statement > operating Expenses
2421000000
Annuals > 1 > income Statement > operating Income
1327000000
Annuals > 1 > income Statement > interest Expense
527000000
Annuals > 1 > income Statement > pretax Income
673000000
Annuals > 1 > income Statement > net Income
1023000000
Annuals > 1 > income Statement > eps
3.9918835758843545
Annuals > 1 > income Statement > dividends Per Share
294000000
Annuals > 1 > income Statement > shares Outstanding
256269999
Annuals > 1 > income Statement > income Tax Expense
-350000000
Annuals > 1 > income Statement > EBITDA
1436000000
Annuals > 1 > income Statement > operating Margin
21.18792910745649
Annuals > 1 > income Statement > total Other Income Expense Net
-654000000
Annuals > 1 > balance Sheet > cash
693000000
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
1857000000
Annuals > 1 > balance Sheet > inventories
1315000000
Annuals > 1 > balance Sheet > total Current Assets
4508000000
Annuals > 1 > balance Sheet > property Plant Equipment
1356000000
Annuals > 1 > balance Sheet > total Assets
12058000000
Annuals > 1 > balance Sheet > payables
1314000000
Annuals > 1 > balance Sheet > short Term Debt
55000000
Annuals > 1 > balance Sheet > long Term Debt
8751000000
Annuals > 1 > balance Sheet > total Liabilities
12128000000
Annuals > 1 > balance Sheet > equity
-70000000
Annuals > 1 > cash Flow > net Income
1023000000
Annuals > 1 > cash Flow > depreciation
236000000
Annuals > 1 > cash Flow > change In Working Capital
-155000000
Annuals > 1 > cash Flow > cash From Operations
799000000
Annuals > 1 > cash Flow > capital Expenditures
261000000
Annuals > 1 > cash Flow > cash From Investing
-260000000
Annuals > 1 > cash Flow > cash From Financing
-569000000
Annuals > 1 > cash Flow > net Change In Cash
-13000000
Annuals > 1 > ratios > PE
3.9918835758843545
Annuals > 1 > ratios > PB
-27.82359989142857
Annuals > 1 > ratios > ROE
-1461.4285714285713
Annuals > 1 > ratios > ROA
8.483994028860508
Annuals > 1 > ratios > FCF
538000000
Annuals > 1 > ratios > Piotroski FScore
3
Annuals > 1 > ratios > fcf Percent
0.08590132524349353
Annuals > 1 > health Score
46
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
6174000000
Annuals > 2 > income Statement > cost Of Revenue
2294000000
Annuals > 2 > income Statement > gross Profit
3880000000
Annuals > 2 > income Statement > operating Expenses
2175000000
Annuals > 2 > income Statement > operating Income
1705000000
Annuals > 2 > income Statement > interest Expense
422000000
Annuals > 2 > income Statement > pretax Income
1122000000
Annuals > 2 > income Statement > net Income
917000000
Annuals > 2 > income Statement > eps
3.5936967264832327
Annuals > 2 > income Statement > dividends Per Share
290000000
Annuals > 2 > income Statement > shares Outstanding
255169000
Annuals > 2 > income Statement > income Tax Expense
205000000
Annuals > 2 > income Statement > EBITDA
1756000000
Annuals > 2 > income Statement > operating Margin
27.615808228053123
Annuals > 2 > income Statement > total Other Income Expense Net
-583000000
Annuals > 2 > balance Sheet > cash
706000000
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
1606000000
Annuals > 2 > balance Sheet > inventories
1003000000
Annuals > 2 > balance Sheet > total Current Assets
3931000000
Annuals > 2 > balance Sheet > property Plant Equipment
1233000000
Annuals > 2 > balance Sheet > total Assets
10955000000
Annuals > 2 > balance Sheet > payables
1132000000
Annuals > 2 > balance Sheet > short Term Debt
57000000
Annuals > 2 > balance Sheet > long Term Debt
8905000000
Annuals > 2 > balance Sheet > total Liabilities
11847000000
Annuals > 2 > balance Sheet > equity
-892000000
Annuals > 2 > cash Flow > net Income
917000000
Annuals > 2 > cash Flow > depreciation
212000000
Annuals > 2 > cash Flow > change In Working Capital
-452000000
Annuals > 2 > cash Flow > cash From Operations
858000000
Annuals > 2 > cash Flow > capital Expenditures
427000000
Annuals > 2 > cash Flow > cash From Investing
-420000000
Annuals > 2 > cash Flow > cash From Financing
-433000000
Annuals > 2 > cash Flow > net Change In Cash
-31000000
Annuals > 2 > ratios > PE
3.5936967264832327
Annuals > 2 > ratios > PB
-2.174085650224215
Annuals > 2 > ratios > ROE
-102.80269058295963
Annuals > 2 > ratios > ROA
8.370607028753993
Annuals > 2 > ratios > FCF
431000000
Annuals > 2 > ratios > Piotroski FScore
2
Annuals > 2 > ratios > fcf Percent
0.06980887593132491
Annuals > 2 > health Score
44
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
6304000000
Annuals > 3 > income Statement > cost Of Revenue
2382000000
Annuals > 3 > income Statement > gross Profit
3922000000
Annuals > 3 > income Statement > operating Expenses
2007000000
Annuals > 3 > income Statement > operating Income
1915000000
Annuals > 3 > income Statement > interest Expense
258000000
Annuals > 3 > income Statement > pretax Income
1529000000
Annuals > 3 > income Statement > net Income
1351000000
Annuals > 3 > income Statement > eps
5.328336996561732
Annuals > 3 > income Statement > dividends Per Share
145000000
Annuals > 3 > income Statement > shares Outstanding
253550029
Annuals > 3 > income Statement > income Tax Expense
178000000
Annuals > 3 > income Statement > EBITDA
1982000000
Annuals > 3 > income Statement > operating Margin
30.37753807106599
Annuals > 3 > income Statement > total Other Income Expense Net
-386000000
Annuals > 3 > balance Sheet > cash
737000000
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
1512000000
Annuals > 3 > balance Sheet > inventories
915000000
Annuals > 3 > balance Sheet > total Current Assets
3760000000
Annuals > 3 > balance Sheet > property Plant Equipment
1203000000
Annuals > 3 > balance Sheet > total Assets
10681000000
Annuals > 3 > balance Sheet > payables
1382000000
Annuals > 3 > balance Sheet > short Term Debt
55000000
Annuals > 3 > balance Sheet > long Term Debt
9125000000
Annuals > 3 > balance Sheet > total Liabilities
12189000000
Annuals > 3 > balance Sheet > equity
-1508000000
Annuals > 3 > cash Flow > net Income
1351000000
Annuals > 3 > cash Flow > depreciation
195000000
Annuals > 3 > cash Flow > change In Working Capital
702000000
Annuals > 3 > cash Flow > cash From Operations
2458000000
Annuals > 3 > cash Flow > capital Expenditures
488000000
Annuals > 3 > cash Flow > cash From Investing
-481000000
Annuals > 3 > cash Flow > cash From Financing
-1333000000
Annuals > 3 > cash Flow > net Change In Cash
667000000
Annuals > 3 > ratios > PE
5.328336996561732
Annuals > 3 > ratios > PB
-1.2778383424403181
Annuals > 3 > ratios > ROE
-89.58885941644562
Annuals > 3 > ratios > ROA
12.64862840558
Annuals > 3 > ratios > FCF
1970000000
Annuals > 3 > ratios > Piotroski FScore
3
Annuals > 3 > ratios > fcf Percent
0.3125
Annuals > 3 > health Score
59
Valuation > metrics > PE
3.9791
Valuation > metrics > PB
2.062783675496689
Valuation > final Score
100
Valuation > verdict
30.1% Undervalued
Profitability > metrics > ROE
17.660044150110377
Profitability > metrics > ROA
3.404255319148936
Profitability > metrics > Net Margin
0.09987515605493133
Profitability > final Score
61
Profitability > verdict
Adequate
Risk > metrics > Debt Equity
13.958057395143488
Risk > metrics > Interest Coverage
2.796875
Risk > final Score
17
Risk > verdict
High
Liquidity > metrics > Current Ratio
4.200178731009831
Liquidity > metrics > Quick Ratio
2.870420017873101
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
100
Prev Valuations > 1
65.47274594095941
Prev Valuations > 2
60.522769915254244
Prev Profitabilities > 0
63
Prev Profitabilities > 1
47
Prev Profitabilities > 2
58
Prev Risks > 0
16
Prev Risks > 1
16
Prev Risks > 2
15
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-14T00:57:46.611Z
Earnings History > 0 > period
2025-09-30
Earnings History > 0 > report Date
2025-10-30
Earnings History > 0 > date
2025-09-30
Earnings History > 0 > before After Market
BeforeMarket
Earnings History > 0 > currency
USD
Earnings History > 0 > eps Actual
1.01
Earnings History > 0 > eps Estimate
0.93
Earnings History > 0 > eps Difference
0.08
Earnings History > 0 > surprise Percent
8.6022
Earnings History > 1 > period
2025-06-30
Earnings History > 1 > report Date
2025-08-05
Earnings History > 1 > date
2025-06-30
Earnings History > 1 > before After Market
BeforeMarket
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
1
Earnings History > 1 > eps Estimate
0.94
Earnings History > 1 > eps Difference
0.06
Earnings History > 1 > surprise Percent
6.383
Earnings History > 2 > period
2025-03-31
Earnings History > 2 > report Date
2025-05-01
Earnings History > 2 > date
2025-03-31
Earnings History > 2 > before After Market
BeforeMarket
Earnings History > 2 > currency
USD
Earnings History > 2 > eps Actual
1.02
Earnings History > 2 > eps Estimate
0.89
Earnings History > 2 > eps Difference
0.13
Earnings History > 2 > surprise Percent
14.6067
Earnings History > 3 > period
2024-12-31
Earnings History > 3 > report Date
2025-02-13
Earnings History > 3 > date
2024-12-31
Earnings History > 3 > before After Market
BeforeMarket
Earnings History > 3 > currency
USD
Earnings History > 3 > eps Actual
0.9
Earnings History > 3 > eps Estimate
0.87
Earnings History > 3 > eps Difference
0.03
Earnings History > 3 > surprise Percent
3.4483
Earnings History > 4 > period
2024-09-30
Earnings History > 4 > report Date
2024-10-31
Earnings History > 4 > date
2024-09-30
Earnings History > 4 > before After Market
BeforeMarket
Earnings History > 4 > currency
USD
Earnings History > 4 > eps Actual
0.87
Earnings History > 4 > eps Estimate
0.9
Earnings History > 4 > eps Difference
-0.03
Earnings History > 4 > surprise Percent
-3.3333
Earnings History > 5 > period
2024-06-30
Earnings History > 5 > report Date
2024-08-06
Earnings History > 5 > date
2024-06-30
Earnings History > 5 > before After Market
BeforeMarket
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
1.12
Earnings History > 5 > eps Estimate
1.08
Earnings History > 5 > eps Difference
0.04
Earnings History > 5 > surprise Percent
3.7037
Earnings History > 6 > period
2024-03-31
Earnings History > 6 > report Date
2024-05-03
Earnings History > 6 > date
2024-03-31
Earnings History > 6 > before After Market
BeforeMarket
Earnings History > 6 > currency
USD
Earnings History > 6 > eps Actual
1.22
Earnings History > 6 > eps Estimate
0.97
Earnings History > 6 > eps Difference
0.25
Earnings History > 6 > surprise Percent
25.7732
Earnings History > 7 > period
2023-12-31
Earnings History > 7 > report Date
2024-02-15
Earnings History > 7 > date
2023-12-31
Earnings History > 7 > before After Market
BeforeMarket
Earnings History > 7 > currency
USD
Earnings History > 7 > eps Actual
0.88
Earnings History > 7 > eps Estimate
0.83
Earnings History > 7 > eps Difference
0.05
Earnings History > 7 > surprise Percent
6.0241
Earnings History > 8 > period
2023-09-30
Earnings History > 8 > report Date
2023-11-02
Earnings History > 8 > date
2023-09-30
Earnings History > 8 > before After Market
BeforeMarket
Earnings History > 8 > currency
USD
Earnings History > 8 > eps Actual
0.87
Earnings History > 8 > eps Estimate
1.06
Earnings History > 8 > eps Difference
-0.19
Earnings History > 8 > surprise Percent
-17.9245
Earnings History > 9 > period
2023-06-30
Earnings History > 9 > report Date
2023-08-08
Earnings History > 9 > date
2023-06-30
Earnings History > 9 > before After Market
BeforeMarket
Earnings History > 9 > currency
USD
Earnings History > 9 > eps Actual
1.31
Earnings History > 9 > eps Estimate
1.01
Earnings History > 9 > eps Difference
0.3
Earnings History > 9 > surprise Percent
29.703
Earnings History > 10 > period
2023-03-31
Earnings History > 10 > report Date
2023-05-04
Earnings History > 10 > date
2023-03-31
Earnings History > 10 > before After Market
BeforeMarket
Earnings History > 10 > currency
USD
Earnings History > 10 > eps Actual
1.08
Earnings History > 10 > eps Estimate
1.16
Earnings History > 10 > eps Difference
-0.08
Earnings History > 10 > surprise Percent
-6.8966
Earnings History > 11 > period
2022-12-31
Earnings History > 11 > report Date
2023-02-16
Earnings History > 11 > date
2022-12-31
Earnings History > 11 > before After Market
BeforeMarket
Earnings History > 11 > currency
USD
Earnings History > 11 > eps Actual
0.81
Earnings History > 11 > eps Estimate
0.9
Earnings History > 11 > eps Difference
-0.09
Earnings History > 11 > surprise Percent
-10
Earnings History > 12 > period
2022-09-30
Earnings History > 12 > report Date
2022-11-03
Earnings History > 12 > date
2022-09-30
Earnings History > 12 > before After Market
BeforeMarket
Earnings History > 12 > currency
USD
Earnings History > 12 > eps Actual
1.32
Earnings History > 12 > eps Estimate
1.09
Earnings History > 12 > eps Difference
0.23
Earnings History > 12 > surprise Percent
21.1009
Earnings History > 13 > period
2022-06-30
Earnings History > 13 > report Date
2022-08-04
Earnings History > 13 > date
2022-06-30
Earnings History > 13 > before After Market
BeforeMarket
Earnings History > 13 > currency
USD
Earnings History > 13 > eps Actual
1.25
Earnings History > 13 > eps Estimate
1.16
Earnings History > 13 > eps Difference
0.09
Earnings History > 13 > surprise Percent
7.7586
Earnings History > 14 > period
2022-03-31
Earnings History > 14 > report Date
2022-05-05
Earnings History > 14 > date
2022-03-31
Earnings History > 14 > before After Market
BeforeMarket
Earnings History > 14 > currency
USD
Earnings History > 14 > eps Actual
1.65
Earnings History > 14 > eps Estimate
1.3
Earnings History > 14 > eps Difference
0.35
Earnings History > 14 > surprise Percent
26.9231
Earnings History > 15 > period
2021-12-31
Earnings History > 15 > report Date
2022-02-17
Earnings History > 15 > date
2021-12-31
Earnings History > 15 > before After Market
BeforeMarket
Earnings History > 15 > currency
USD
Earnings History > 15 > eps Actual
1.37
Earnings History > 15 > eps Estimate
1.24
Earnings History > 15 > eps Difference
0.13
Earnings History > 15 > surprise Percent
10.4839
Earnings History > 16 > period
2021-09-30
Earnings History > 16 > report Date
2021-11-11
Earnings History > 16 > date
2021-09-30
Earnings History > 16 > before After Market
BeforeMarket
Earnings History > 16 > currency
USD
Earnings History > 16 > eps Actual
1.67
Earnings History > 16 > eps Estimate
1.44
Earnings History > 16 > eps Difference
0.23
Earnings History > 16 > surprise Percent
15.9722
Earnings History > 17 > period
2021-06-30
Earnings History > 17 > report Date
2021-08-12
Earnings History > 17 > date
2021-06-30
Earnings History > 17 > before After Market
BeforeMarket
Earnings History > 17 > currency
USD
Earnings History > 17 > eps Actual
1.72
Earnings History > 17 > eps Estimate
1.4
Earnings History > 17 > eps Difference
0.32
Earnings History > 17 > surprise Percent
22.8571
Earnings History > 18 > period
2021-03-31
Earnings History > 18 > report Date
2021-06-21
Earnings History > 18 > date
2021-03-31
Earnings History > 18 > before After Market
BeforeMarket
Earnings History > 18 > currency
USD
Earnings History > 18 > eps Actual
1.58
Earnings History > 18 > eps Estimate
1.52
Earnings History > 18 > eps Difference
0.06
Earnings History > 18 > surprise Percent
3.9474
Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding or hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
0.02Next Payout:
Dec 11, 2025Yield:
1.1158 %How Investors Are Reacting To Organon (OGN) As Barclays Joins Growing Analyst Skepticism simplywall.st
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
HOLD
Target Price:
$9.6667
Analyst Picks
Strong Buy
0
Buy
2
Hold
3
Sell
2
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Earnings Ratio (P/E)
-
Very High
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Medium
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
High
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Medium
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 84.86% of the total shares of Organon & Co
1.
Vanguard Group Inc(12.4161%)
since
2025/06/30
2.
BlackRock Inc(11.9793%)
since
2025/06/30
3.
iShares Core S&P Small-Cap ETF(5.9467%)
since
2025/08/31
4.
Massachusetts Financial Services Company(3.9379%)
since
2025/06/30
5.
State Street Corp(3.6623%)
since
2025/06/30
6.
Millennium Management LLC(3.4968%)
since
2025/06/30
7.
Vanguard Total Stock Mkt Idx Inv(3.1228%)
since
2025/07/31
8.
LSV Asset Management(3.0733%)
since
2025/06/30
9.
Vanguard Small Cap Index(2.4257%)
since
2025/07/31
10.
UBS Group AG(2.2925%)
since
2025/06/30
11.
Morgan Stanley - Brokerage Accounts(2.2104%)
since
2025/06/30
12.
Citadel Advisors Llc(2.1012%)
since
2025/06/30
13.
Nordea Investment Mgmt Bank Demark A/s(1.8864%)
since
2025/06/30
14.
Dimensional Fund Advisors, Inc.(1.7802%)
since
2025/06/30
15.
Geode Capital Management, LLC(1.6909%)
since
2025/06/30
16.
Vanguard Small Cap Value Index Inv(1.5577%)
since
2025/07/31
17.
MFS Mid Cap Value Equity(1.5231%)
since
2025/06/30
18.
MFS Mid Cap Value A(1.5022%)
since
2025/07/31
19.
Charles Schwab Investment Management Inc(1.3784%)
since
2025/06/30
20.
Bank of New York Mellon Corp(1.377%)
since
2025/06/30
21.
Kahn Brothers & CO Inc /DE/(1.3425%)
since
2025/06/30
22.
AQR Capital Management LLC(1.252%)
since
2025/06/30
23.
Private Management Group Inc(1.2063%)
since
2025/06/30
24.
Vanguard Institutional Extnd Mkt Idx Tr(1.075%)
since
2025/07/31
25.
Gotham Asset Management, LLC(1.0407%)
since
2025/06/30
26.
iShares S&P Small-Cap 600 Value ETF(0.9321%)
since
2025/08/31
27.
SPDR® Portfolio S&P 600™ Sm Cap ETF(0.8807%)
since
2025/08/29
28.
Brandywine Global Investment Mgmt LLC(0.8704%)
since
2025/06/30
29.
Northern Trust Corp(0.8001%)
since
2025/06/30
30.
Vanguard Tax-Managed Small Cap Adm(0.707%)
since
2025/07/31
31.
Vanguard Equity-Income Inv(0.687%)
since
2025/06/30
32.
Russell Inv Tax-Managed US Large Cap S(0.6744%)
since
2025/07/31
33.
First Trust Health Care AlphaDEX® ETF(0.6195%)
since
2025/08/28
34.
SPDR® S&P 600 Small Cap Value ETF(0.5711%)
since
2025/08/31
35.
Fidelity Extended Market Index(0.5424%)
since
2025/07/31
36.
WisdomTree US SmallCap Dividend ETF(0.5315%)
since
2025/08/29
37.
Nordea 1 - Glb Sust Stars Equity BI USD(0.5124%)
since
2025/07/31
38.
Schwab US Small-Cap ETF™(0.4748%)
since
2025/08/30
39.
Principal SmallCap S&P 600 Idx SP(0.3946%)
since
2025/07/31
40.
Vanguard High Dividend Yield ETF(0.3834%)
since
2025/07/31
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-09-30
EPS Actual
1.01
EPS Estimate
0.93
EPS Difference
0.08
Surprise Percent
8.6022%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.